Proactive Multifactorial Intervention Strategy Reduces the Risk of Cardiovascular Disease Estimated with Region-Specific Risk Assessment Models in Pacific Asian Patients Participating in the CRUCIAL Trial

Eun Joo Cho,† Jae Hyung Kim,‡ Santosh Sutradhar,* Carla Yunis,§ and Mogens Westergaard,* on behalf of the CRUCIAL Trial Investigators

1Department of Cardiology, St Paul’s Hospital, The Catholic University of Korea, Seoul, Korea; 2Pfizer Inc, New York, NY, USA

* Santosh Sutradhar and Mogens Westergaard were employees of Pfizer Inc at the time when the study was conducted.

Received: 14 April 2013
Accepted: 30 September 2013

Address for Correspondence:
Jae Hyung Kim, MD
Department of Cardiology, St Paul’s Hospital, The Catholic University of Korea, 180 Wangsan-ro, Dongdaemun-gu, Seoul 130-709, Korea
Tel: +82.2-958-2388, Fax: +82.2-968-7250
E-mail: jhkim480kr@naver.com

This study was funded by Pfizer Inc. (2006-2010, ClinicalTrials.gov registration number: NCT00407537).

INTRODUCTION

The Cluster Randomized Usual Care versus Caduet Intervention Assessing Long-Term Risk (CRUCIAL) trial (1) was designed to assess, in a real-world clinical practice setting, whether calculated Framingham coronary heart disease (CHD) risk (2) could be improved over usual care (UC) if 2 important cardiovascular (CV) risk factors, blood pressure (BP) and cholesterol, were targeted simultaneously with a proactive multifactorial intervention (PMI) strategy based on single-pill amlodipine/atorvastatin (SPAA). The combination of amlodipine and atorvastatin was chosen because these drugs have outcomes data from previous clinical trials (3, 4). The CRUCIAL trial demonstrated among patients with hypertension and additional CV risk factors that a greater reduction in calculated Framingham CHD risk (2) could be achieved using a PMI strategy versus UC (1).

Overall, 31% of patients recruited in the CRUCIAL trial resided in the Pacific Asian (PA) region. In contrast with most Western countries, the prevalence of stroke is higher than CHD in both China and Japan (5, 6). The nature of stroke also tends to be different among some PA populations, where strokes are more often hemorrhagic than ischemic, compared with Caucasian populations (7). Furthermore, there is evidence to suggest that the strength of the association between some CV risk factors (e.g. hypertension) and CV outcomes may differ among Asian populations compared with Western populations (8, 9).

In spite of these differences, many worldwide hypertension management guidelines recommend use of the Framingham coronary heart disease risk equation to guide treatment decisions. This subanalysis of the recently published CRUCIAL trial compared the treatment-related reductions in calculated CHD and stroke risk among Pacific Asian (PA) patients using a variety of region-specific risk assessment models. As a result, greater reductions in systolic and diastolic blood pressure, low-density lipoprotein cholesterol, and triglycerides were observed in the proactive multifactorial intervention (PMI) arm compared with the usual care arm at Week 52 for PA patients. The relative percentage change in 10-yr CHD risk between baseline and Week 52 in the PMI versus usual care arms was greatest using the NIPPON DATABO fatal CHD model (LS [least square] mean difference -42.6%), and similar in the SCORE fatal CHD and Framingham total CHD models (LS mean difference -29.4% and -30.8%, respectively). The single-pill based PMI approach is consistently effective in reducing cardiovascular disease risk, evaluated using a variety of risk assessment models. (ClinicalTrials.gov registration number: NCT00407537)

Key Words: Cardiovascular Diseases; Risk Factors; Hypertension; Clinical Trial; Antihypertensive Agents; Anticholesteremic Agents
accurate risk prediction in some ethnic groups (13). Indeed, the observed variations in CV risk profiles among different populations has led to different CV risk assessment tools being developed from specific geographic and ethnic cohorts (2, 14, 15). Accurate risk prediction is particularly important among PA populations as, in 2005, over half of the cases of CVD worldwide occurred in this region (16), and this is predicted to rise further as parts of the region continue to undergo rapid urbanization (16).

To confirm the applicability of the CRUCIAL trial results among patients residing in the PA region, it is important to determine if the reported treatment-related reductions in calculated Framingham CHD risk (2) are consistent when risk is calculated using region-specific risk assessment tools. In this CRUCIAL trial subanalysis, we compare the treatment-related reductions in calculated CHD and stroke risk observed in the CRUCIAL trial using the National Integrated Project for Prospective Observation of Non-communicable Disease And its Trends in the Aged, 1980 (NIPPON DATA80) (15), the Systematic Coronary Risk Evaluation (SCORE) for low-risk countries (14), and the Framingham total CHD risk equation (2) among PA patients enrolled in the CRUCIAL trial.

MATERIALS AND METHODS

Study design and patients
This CRUCIAL trial subanalysis utilized baseline and endpoint data from 448 patients residing in the PA region (1). The CRUCIAL trial design and principal results have previously been published (1). In brief, the CRUCIAL trial was a 12-month, prospective, multinational, open-label, parallel-design, cluster-randomized trial. Eligible patients were men and women aged between 35 and 79 yrs at baseline with hypertension (untreated: systolic BP [SBP] ≥ 160 mmHg and/or diastolic BP [DBP] ≥ 100 mmHg; treated: SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg; diabetes SBP > 130 mmHg and/or DBP > 80 mmHg), 3 or more additional CV risk factors, no history of CHD, total cholesterol (TC) ≤ 6.5 mM/L, and not receiving statin therapy. Two treatment strategies were compared: a PMI strategy, based on SPAA, and UC (Fig. 1).

Comparison of CV risk assessment tools
In this subanalysis, baseline and endpoint CHD and stroke risks were calculated using the following risk assessment tools: 1) NIPPON DATA80 10-yr probability of death due to CHD (15); 2) NIPPON DATA80 10-yr probability of death due to stroke (15); 3) SCORE 10-yr risk of fatal CHD for low-risk countries (14); 4) SCORE 10-yr risk of fatal non-CHD CVD for low-risk countries (14); and 5) Framingham 10-yr risk of combined fatal and non-fatal CHD (2) (Table 1).

The Framingham total CHD risk equation (2) was the primary endpoint in the CRUCIAL trial. Although the Framingham stroke model (17) was evaluated as a secondary endpoint in the CRUCIAL trial, it has not been evaluated in this subanalysis because it calculates the combined risk of fatal and nonfatal stroke, so is not directly comparable with the NIPPON DATA80 fatal stroke (15) or SCORE fatal non-CHD CVD (14) models.

The NIPPON DATA80 (15) risk-assessment chart
Death from stroke and CHD during follow-up was determined from the National Vital Statistics register (coded using the 9th and 10th International Classification of Disease [ICD]). Separate charts were developed for the 10-yr probabilities for death by CHD, stroke, and combined CHD/stroke. Risk factors in the models included gender, age, SBP, TC, diabetes (defined as casual glucose level ≥ 200 mg/dL), and smoking status.

The SCORE (14) tool
Outcomes were defined using ICD-9 codes for CV mortality. Separate models were developed for low- and high-risk coun-

Fig. 1. Flow of PA patients through the CRUCIAL trial. *Treated patients with baseline and 1 or more post-baseline efficacy measurements. CRUCIAL, Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-Term Risk; PA, Pacific Asian; PMI, proactive multifactorial intervention; UC usual care.

http://vkms.org http://dx.doi.org/10.3346/jkms.2013.28.12.1741
tries. Models were developed for the 10-yr risk of fatal CHD and 10-yr risk of fatal non-CHD CVD. Risk factors in the models included gender, age, SBP, TC, and smoking status.

The Framingham equation (2)
CHD was defined as angina, recognized and unrecognized myocardial infarction, coronary insufficiency, and CHD death. Risk factors included in the model were age, gender, TC, high-density lipoprotein cholesterol (HDL-C), SBP, DBP, diabetes (defined as treatment with insulin or oral hypoglycemic agents, or casual blood glucose > 150 mg/dL at 2 clinic visits or fasting glucose > 140 mg/dL), and cigarette smoking status.

Efficacy measures
The primary evaluation of this subanalysis was to compare the overall change in CHD risk between baseline and Week 52 as calculated by the NIPPON DATA80 10-yr probability of death due to CHD (15), SCORE 10-yr risk of CHD for low-risk countries (14), and Framingham 10-yr risk of total CHD (2).

Secondary efficacy evaluations included the change in non-CHD risk between baseline and Week 52 as calculated by the NIPPON DATA80 10-yr probability of death due to stroke (15), SCORE 10-yr risk of non-CHD CVD for low-risk countries (14), absolute treatment-related change from baseline in SBP and DBP, and percentage treatment-related change from baseline in low-density lipoprotein cholesterol (LDL-C) and TC.

Statistical methods
Continuous variables were summarized as mean values ± standard deviation (SD) and categorical variables as percents. Differences between the PMI and UC arms were assessed using least square (LS) means, 95% confidence intervals (CI), and P values. They were calculated using a mixed-effects linear model that included value at a given time point as the response variable; and treatment group, country, and baseline value as explanatory variables. A compound-symmetry variance-covariance matrix was used for patients from the same site, and patients' site was treated as a random effect in the mixed-effects model. All statistical tests were 2-sided and evaluated at the 5% significance level. Last observation carried forward was used for missing measurements.

Ethics statement
The study conformed to good clinical practice guidelines and was conducted in accordance with the Declaration of Helsinki. The protocol and all subsequent amendments to the protocol were reviewed and ratified by central and regional ethical review boards (Pfizer Pharmaceuticals Korea Ltd, IRB approval number: AJIRB-CT4-06-220). Patients gave written informed consent to participate in the trial before the study investigators were randomized. The study was registered with ClinicalTrials.gov (NCT00407537).

RESULTS

Patient population
The majority of PA patients enrolled in the CRUCIAL trial resided in Republic of Korea (35.4%), followed by Indonesia (21.4%), Taiwan (16.9%), the Philippines (15.3%), Malaysia (6.5%), and Thailand (4.5%).

At baseline, those in the PMI arm had significantly higher SBP and DBP than the UC arm: 151.0/87.9 vs 143.3/84.1 mmHg, respectively (Table 2). Patients were slightly younger in the PMI arm compared with the UC arm: 61.5 vs 63.6 yr, respectively (Table 2). Overall, the baseline mean CV risk scores were comparable between the 2 treatment arms when calculated using the NIPPON DATA80 (15), SCORE (14), and Framingham (2) risk equations (Table 3).

At baseline, the risk of fatal stroke was lower than the risk of fatal CHD in both the PMI and UC arms (2.5% vs 3.3%) and UC arms (2.3% vs 3.1%).

Table 1. Comparison of risk assessment tools

| Risk model                  | Population | Follow-up (yr) | 10-yr endpoint | Risk factors included |
|-----------------------------|------------|----------------|----------------|----------------------|
| NIPPON DATA80-CHD (15)      | Japan      | 19             | CHD death      | √        |
| NIPPON DATA80-Stroke (15)   | Japan      | 19             | Stroke death   | √        |
| SCORE-CHD (14)              | Europe     | 10-26          | CHD death      | √        |
| SCORE – non-CHD CVD (14)    | Europe     | 10-26          | Non-CHD CVD    | √        |
| Framingham (2)              | USA        | 12             | Fatal and nonfatal CHD events | √        |

CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HDL-C, high-density lipoprotein cholesterol; NIPPON DATA80, National Integrated Project for Prospective Observation of Non-Communicable Disease and Its Trends in the Aged, 1980; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation; TC, total cholesterol.
Risk assessments
The absolute percentage change in fatal CHD risk between baseline and Week 52 in the PMI versus UC arms was similar when calculated using the NIPPON DATA80 fatal CHD model (15) and SCORE fatal CHD model (14) (LS mean difference -0.5% [95% CI -0.67, -0.35] and -0.9% [95% CI -1.22, -0.57], respectively; Fig. 2). The absolute difference between the PMI and UC arms between baseline and Week 52, as calculated by the Framingham equation for total CHD events (2), was -6.3% (95% CI -7.76, -4.85).

The relative percentage change in 10-yr CHD risk between baseline and Week 52 in the PMI versus UC arms was greatest using the NIPPON DATA80 fatal CHD model (15) (LS mean difference -42.6%), and similar in the SCORE fatal CHD (14) and Framingham total CHD models (2) (LS mean difference -29.4% and -30.8%, respectively; Fig. 3). This could be driven by the fact that there was almost no change in NIPPON DATA80 fatal CHD risk in the UC arm at Week 52 (absolute change -0.1% and relative percentage change +5.8%; Fig. 2, 3), while there were small reductions in risk from baseline in the UC arm as calculated by the other 2 risk scores (Fig. 2, 3).

Table 2. Baseline characteristics of the PA CRUCIAL population

| Parameters                  | PMI (n = 247) | UC (n = 201) | P value |
|-----------------------------|--------------|-------------|---------|
| Male, No. (%)               | 162 (65.6)   | 122 (60.7)  | 0.285   |
| Age (yr, mean ± SD)         | 61.5 ± 8.9   | 63.6 ± 8.9  | 0.019   |
| Current smoker, No. (%)     | 74 (30.2)    | 47 (23.6)   | 0.121   |
| Type 2 diabetes, No. (%)    | 143 (57.9)   | 120 (59.7)  | 0.699   |
| BMI (kg/m², mean ± SD)      | 25.6 ± 3.8   | 26.3 ± 3.7  | 0.064   |
| SBP (mmHg, mean ± SD)       | 151.0 ± 17.4 | 143.3 ± 15.9| < 0.001 |
| DBP (mmHg, mean ± SD)       | 87.9 ± 11.1  | 84.1 ± 9.2  | < 0.001 |
| Heart rate (bpm, mean ± SD) | 72.6 ± 10.5  | 73.2 ± 10.7 | 0.544   |
| TC (mg/dL, mean ± SD)       | 194.6 ± 30.3 | 194.0 ± 29.8| 0.831   |
| LDL-C (mg/dL, mean ± SD)    | 114.2 ± 28.3 | 113.0 ± 28.7| 0.659   |
| HDL-C (mg/dL, mean ± SD)    | 47.2 ± 12.3  | 47.3 ± 12.6 | 0.997   |
| TG (mg/dL, mean ± SD)       | 169.6 ± 84.9 | 172.6 ± 83.1| 0.711   |

*Treated patients with baseline and ≥ 1 post-baseline efficacy measurements; †BP values were measured at baseline (Week 0), whereas information for all other variables listed was collected during screening. bpm, beats per minute; BMI, body mass index; BP, blood pressure; CRUCIAL, Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-Term Risk; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PA, Pacific Asian; PMI, proactive multifactorial intervention; SBP, systolic blood pressure; SD, standard deviation; TC, total cholesterol; TG, triglyceride; UC, usual care.

Table 3. Baseline risk scores of the PA CRUCIAL population

| Assessment tools                  | Calculated risk scores (mean ± SD) | P value |
|-----------------------------------|------------------------------------|---------|
| NIPPON DATA80 10-yr fatal CHD risk (15) | 1.3 ± 1.5                         | 0.548   |
| NIPPON DATA80 10-yr fatal stroke risk (15) | 3.0 ± 3.5                         | 0.812   |
| SCORE 10-yr fatal CHD risk (14)     | 3.3 ± 3.3                          | 0.553   |
| SCORE 10-yr fatal non-CHD CVD risk (14) | 2.5 ± 2.6                         | 0.471   |
| Framingham 10-yr fatal and nonfatal CHD risk (2) | 22.0 ± 12.0                        | 0.606   |

CHD, coronary heart disease; CVD, cardiovascular disease; NIPPON DATA80 (15), National Integrated Project for Prospective Observation of Non-Communicable Disease and Its Trends in the Aged, 1980; PMI, proactive multifactorial intervention; SCORE (14), Systematic Coronary Risk Evaluation; SD, standard deviation; UC, usual care.
BP and lipid parameters

Greater reductions in SBP, DBP, LDL-C, and TC were observed in the PMI arm compared with the UC arm at Week 52 for PA patients. PA patients in the UC arm demonstrated a small increase in TC and LDL-C between baseline and Week 52 (Fig. 5).

DISCUSSION

This subanalysis of the CRUCIAL trial has demonstrated among 448 patients residing in the PA region that, compared with UC, the PMI approach was consistently more effective in reducing calculated CHD and CVD risk using various region-specific risk assessment models (2, 14, 15), despite the differences in CV risk assessment scores when calculated using these models.

High BP is estimated to account for 6% of deaths worldwide (18) and is the most common treatable risk factor for CVD (19, 20). During the last 30 yr, hypertension treatment has improved dramatically, contributing to a decrease in the incidence of mortality due to stroke and CHD (21). However, the majority of patients’ BP remains uncontrolled in all societies, and the decline in CVD, particularly stroke, has slowed in some countries (11).

Dyslipidemia is among the top 5 major risk factors leading to CVD (9). Its treatment has been shown to improve prognosis: morbidity and mortality is substantially reduced in successfully treated compared with nontreated dyslipidemic controls (22, 23). However, in daily clinical practice the treatment and control of dyslipidemia remains suboptimal (24).

The aim of this subanalysis of the CRUCIAL trial was to compare, among a PA population, the treatment-related reductions in calculated CHD and non-CHD risk using region-specific risk scoring methods, driven by reductions in BP and cholesterol, rather than to compare the predictive capacity of each risk model. All 5 risk models showed a treatment-related reduction in CHD and stroke risk at Week 52 in the PMI arm compared with the UC arm. It is beyond the scope of this analysis to look at the actual predictive capacity of these models, as outcomes data on stroke and CHD events were not collected during the CRUCIAL trial.

In our analysis, there were differences in the baseline risk scores calculated by the NIPPON DATA80 (15), SCORE (14), and Framingham (2) models. At baseline, compared with the SCORE model (14), the NIPPON DATA80 model (15) gave lower risk scores for fatal CHD risk and higher risk scores for fatal stroke in both the PMI and UC arms. In the NIPPON DATA80 model (15), the risk of fatal stroke was higher than the risk of fatal CHD in both the PMI and UC arms; the reverse was seen when risks were calculated using the SCORE model (14). This may reflect differences in the event-rates seen in the populations from which the risk scores were developed (Japanese versus European).

It is also important to note when comparing these tools that the definition of the predicted outcome varies according to the risk model used. The NIPPON DATA80 (15) and SCORE (14) models calculate the risk of fatal CHD defined by ICD codes 9 and 10, whereas the Framingham (2) model calculates fatal and nonfatal CHD based on outcome data collected during patient visits and hospital records. This may partly explain the higher baseline risk seen in the Framingham equation (2) vs NIPPON
Hence, the risk of CVD, especially of CHD assessed using the SBP, TC, and LDL-C, than the UC arm, in which taking of a lip

The routine use of the PMI strategy for the treatment of hy

in the NIPPON DATA80 model (15). TC is not used in the NIP

Diabetes was defined as a casual glucose level of ≥ 200 mg/dL

level of > 140 mg/dL in the Framingham model (2), whereas

blood glucose level of > 150 mg/dL at 2 clinic visits, or fasting glucose

in the CRUCIAL trial population. Diabetes was defined as treat

els (14). This may be an important factor in predicting CV risk

PON DATA80 models (15), but not in either of the SCORE mod

other plausible explanations for observed differences in cal

in Asians compared with Caucasians (25). The Study of Health

risk factors and associated events in the population from which

They are derived. The NIPPON DATA80 model (15) was devel

from a Japanese population, the SCORE model (14) from a

European population, and the Framingham model (2) from a

predominately Caucasian middle-class population in the Unit

The Singapore Cardiovascular Cohort Study suggested that hy

may have a greater relative effect on CHD in Asians compared with Caucasians (25). The Study of Health Assessment and Risk in Ethnic Groups demonstrated that there may be greater potential for plaque rupture and thrombotic events among South Asians compared with the populations of Europe or China (8). The INTERHEART China study found stronger associations between myocardial infarction and certain CV risk factors, such as diabetes and stress, in Chinese populations compared with other regions of the world (26). Several studies have found that the Framingham CHD risk model (2) overestimated CHD risk in the Chinese population (27, 28). Indeed, when the Framingham investigators tested their score among different ethnic groups, they found that the original equations required recalibrating for populations with different CV event rates (13).

There are also differences in the risk factors included in the models and how the risk factors were defined. The Framing

ham total CHD model (2), where diabetes was included as a risk factor (rather than a CHD risk equivalent), was chosen by

the CRUCIAL trial investigators to reflect their study’s inclusion criteria (1). Diabetes is also included as a risk factor in both NIP

PON DATA80 models (15), but not in either of the SCORE models (14). This may be an important factor in predicting CV risk among PA patients who had a high incidence of diabetes (59%) in the CRUCIAL trial population. Diabetes was defined as treatment with insulin or oral hypoglycemic agents, casual blood glucose level of > 150 mg/dL at 2 clinic visits, or fasting glucose level of > 140 mg/dL in the Framingham model (2), whereas diabetes was defined as a casual glucose level of ≥ 200 mg/dL in the NIPPON DATA80 model (15). TC is not used in the NIP

PON DATA80 stroke model (15) (Table 1), and HDL-C and DBP are not used in either the NIPPON DATA80 (15) or SCORE (14) models.

The routine use of the PMI strategy for the treatment of hy

pertension is more effective in reducing CV risk, by controlling SBP, TC, and LDL-C, than the UC arm, in which taking of a lip

id-lowering agent depended on the clinician’s decision (Fig. 5).

Hence, the risk of CVD, especially of CHD assessed using the

NIPPON DATA80, SCORE, and Framingham systems was consis

tently and significantly reduced by the PMI strategy compared

with the UC arm. However, the risk reduction of non-CHD us

ing the PMI strategy was not outstanding compared with the

UC arm when assessed by NIPPON DATA80 because the pa

tients’ lipid profile was not included in the NIPPON DATA80

10-yr fatal stroke risk system (Table 1). This means that the ad

vantages of the lipid-lowering effects of the PMI arm were not taken into account by the NIPPON DATA80 10-yr fatal stroke risk system. The relative change in 10-yr fatal non-CHD risk from baseline to Week 52 in the PMI treatment arm among PA patients was -12.2% as calculated by NIPPON DATA80 (Fig. 4). Therefore, these results suggest that the PMI strategy is effective in reducing the risk of fatal stroke in the PA region.

The CRUCIAL trial was designed as a relatively short-term intervention (52 weeks) for patients at moderate CV risk, and data on actual CV outcomes were not collected. Calculated CHD and stroke risks were evaluated as a surrogate index for CV outcomes. We believe that comparing the reduction in CV risk after treatment with a PMI strategy (based on the inclusion of SPAA in the patient’s treatment regimen) using different region-specific risk assessment tools is clinically important. In the UC arm, physicians made a voluntary decision about whether or not to prescribe statins and which statin to use, based on their best clinical judgment. In daily practice, physicians prescribe a range of drugs to manage individual patients with hypertension and dyslipidemia. In the CRUCIAL trial, both BP and lipid parameters were reduced to a greater extent in the PMI arm (SPAA-based treatment) compared with the UC arm. This led to a greater reduction in calculated CHD and CVD risk in the PMI arm using each of the risk-scoring methods evaluated in this subanalysis.

Limitations of this post hoc subgroup analysis include the small sample size: only 448 individuals in the CRUCIAL trial resided in the PA region, which will give less precise estimates. An additional limitation is that country of residence was used as a proxy for ethnicity in this analysis, so some misclassification bias may have arisen. Moreover, since multiple comparisons have been made without controlling for overall family-wise error rate, caution should be made when interpreting these results. However, despite these limitations, this study has shown that, among PA patients with hypertension and additional CV risk factors, the PMI treatment strategy is an effective approach to reducing calculated CHD risk using a range of region-specific risk assessment tools.

In conclusion, the PMI approach based on simultaneously targeting BP and cholesterol with an SPAA-based regimen, is more effective than UC in reducing CHD and stroke risk (calculated using a variety of region-specific risk assessment models) for physicians treating PA patients with hypertension and additional CV risk factors in their daily practice. Differences exist in
the risk scores calculated using the different region-specific risk assessment tools. It remains to be seen whether an overall risk score tool can be developed that is more adaptable and applicable to different populations and ethnicities with varying risk factors and patterns of CVD.

ACKNOWLEDGMENTS

This study was sponsored by Pfizer Inc. Medical writing support was provided by Sarah Partridge and Penny Gorrinage of Engage Scientific Solutions and funded by Pfizer Inc. The authors thank Professor Hirotsugu Ueshima and the NIPPON DATA80 Research Group for their permission to use NIPPON DATA80, and also Professor Katsuuki Miura at the Shiga University of Medical Science for kindly reviewing the manuscript. The authors also thank all investigators and co-investigators in the participating countries of the CRUCIAL trial.

DISCLOSURE

EJ Cho and JH Kim have served as consultants, received travel expenses or payment for speaking at meetings, or received funding for research from one or more pharmaceutical companies (including Pfizer Inc, who sponsored this study) that market BP-lowering or lipid-lowering drugs. C Yunis is an employee of Pfizer Inc. S Sutradhar and M Westergaard were employees of Pfizer Inc at the time that this study was conducted. All authors provided input for this sub-analysis, interpreted the results and drafted/reviewed the paper and approved the final version but objectively conducted with fairness.

REFERENCES

1. Zamorano J, Erdine S, Pavia A, Kim JH, Al-Khadra A, Westergaard M, Sutradhar S, Yunis C; CRUCIAL Investigators. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011; 27: 821-33.
2. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
4. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McNees GT, et al. Prevention of coronary and stroke events with atorvastatin in patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
5. Lida M, Ueda K, Okayama A, Kodama K, Sawai K, Shibata S, Tanaka S, Kejinkai T, Horibe H, Minowa M, et al. Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese: Nippon data 80. J Hum Hypertens 2003; 17: 851-7.
6. Zhou B, Zhang H, Wu Y, Li Y, Yang J, Zhao L, Zhang X. Ecological analysis of the association between incidence and risk factors of coronary heart disease and stroke in chinese populations. CVD Prevention 1998; 1: 207-16.
7. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104: 2855-64.
8. Anand SS, Yusuf S, Vakas V, Devanesen S, Teo KK, Montague PA, Kelmatten L, Yi C, Lonn E, Gerstein H, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2006; 356: 279-84.
9. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet 2004; 364: 937-52.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. 2007 guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
13. D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-7.
14. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetière P, Jousilahti P, Keil U, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
15. NIPPON DATA80 Research Group. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 2006; 70: 1249-55.
16. World Health Organization Regional Offices for South-East Asia and the Western Pacific. Chapter 8: priority noncommunicable diseases and conditions. Health in Asia and the Pacific, 2008.
17. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. *Probability of stroke: a risk profile from the Framingham Study*. Stroke 1991; 22: 312-8.

18. Murray CJ, Lopez AD. *Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study*. Lancet 1997; 349: 1436-42.

19. Lee HS, Park YM, Kwon HS, Lee JH, Park YJ, Lim SY, Lee SH, Yoon KH, Son HY, Kim DS, et al. *Prevalence, awareness, treatment, and control of hypertension among people over 40 years old in a rural area of South Korea: the Chungju Metabolic Disease Cohort (CMC) Study*. Clin Exp Hypertens 2010; 32: 166-78.

20. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatespa P, Stegmayr B, Thamm M. *Hypertension treatment and control in five European countries, Canada, and the United States*. Hypertension 2004; 43: 10-7.

21. Lenfant C. *Reflections on hypertension control rates: a message from the director of the National Heart, Lung, and Blood Institute*. Arch Intern Med 2002; 162: 131-2.

22. Brown BG, Stukovsky KH, Zhao XQ. *Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials*. Curr Opin Lipidol 2006; 17: 631-6.

23. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. *Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy*. J Am Coll Cardiol 2006; 48: 438-45.

24. Steinhein-Thiessen E, Bramlage P, Lösch C, Hauner H, Schunkert H, Vogt A, Wasem J, Jöckel KH, Moebus S. *Dyslipidemia in primary care: prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)*. Cardiovasc Diabetol 2008; 7: 31.

25. Lee J, Heng D, Chia KS, Chew SK, Tan BY, Hughes K. *Risk factors and incident coronary heart disease in Chinese, Malay and Asian Indian males: the Singapore Cardiovascular Cohort Study*. Int J Epidemiol 2001; 30: 983-8.

26. Teo KK, Liu L, Chow CK, Wang X, Islam S, Jiang L, Sanderson JE, Rangarajan S, Yusuf S. INTERHEART Investigators in China. *Potentially modifiable risk factors associated with myocardial infarction in China: the INTERHEART China Study*. Heart 2009; 95: 1857-64.

27. Barzi F, Patel A, Gu D, Sritara P, Lam TH, Rodgers A, Woodward M. *Cardiovascular risk prediction tools for populations in Asia*. J Epidemiol Community Health 2007; 61: 115-21.

28. Wu Y, Liu X, Li Y, Zhao L, Chen Z, Li Y, Rao X, Zhou B, Detrano R, et al. *Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults*. Circulation 2006; 114: 2217-25.